Announcements Trials
Browse Landscape

Phase

Phase 2 32Phase NA 12Phase 3 8Phase 4 6Phase 2/3 5Phase EARLY_PHASE1 3Phase 1 3Phase 1/2 2

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 12OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 1

Conditions

Recurrence 1Neoplasms 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 415Radiotherapy 274fludarabine 237Gemcitabine 210Cisplatin 202Nivolumab 184pembrolizumab 181Paclitaxel 176Carboplatin 167Magnetic Resonance Spectroscopy 163fludarabine phosphate 156Irinotecan 134Bevacizumab 133Cytarabine 128Capecitabine 124Temozolomide 123Specimen Handling 122Radiosurgery 117Docetaxel 116Biopsy 115Ipilimumab 114Dexamethasone 113Radiation 109Oxaliplatin 109Fluorouracil 109Etoposide 108Rituximab 107Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Tablets × Clear all
NCT05330377 2023-04-25

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

University of Kentucky

Phase 1 Withdrawn
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT01173913 2019-01-10

Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir

The Netherlands Cancer Institute

Phase 1 Completed
57 enrolled
Tumor-Agnostic

Neoplasms

NCT00667485 2014-01-17

Rapamycin Plus Bevacizumab in Advanced Cancers

University of Chicago

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡